Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8440339 | 0.86 | ALDH1A1 (0.59) | ALDH1A1MAPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL6046664 | 0.85 | ALDH1A1 (0.52) | ALDH1A1MAPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL2388312 | 0.85 | ALDH1A1 (0.67) | ALDH1A1MAPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL377491 | 0.85 | ALDH1A1 (0.67) | ALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL10639506 | 0.84 | ALDH1A1 (0.49) | ALDH1A1MAPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL8587397 | 0.84 | ALDH1A1 (0.56) | ALDH1A1MAPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL9519331 | 0.84 | ALDH1A1 (0.56) | ALDH1A1MAPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL15987432 | 0.84 | ALDH1A1 (0.66) | ALDH1A1MAPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL4573720 | 0.83 | KCNJ1 (0.65) | ALDH1A1MAPTLMNA | |
| SCHEMBL10633269 | 0.83 | ALDH1A1 (0.47) | ALDH1A1MAPTLMNASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1289498-C | 1-methylcarbapenem derivatives | SANKYO CO (JP) | 2006-12-13 | — | — | CN | disclosed |
| EP-1340757-B1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO CO (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-7001897-B2 | 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| CN-1486317-A | 1-methylcarbapenem derivatives | ������������ʽ���� | 2004-03-31 | — | — | CN | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |
| CN-1228087-A | Substituted pyrimidine derivatives and their pharmaceutical use | ZENECA LTD (GB) | 1999-09-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | ALDH1A1 637/4885MAPT 2574/4885LMNA 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.